- When oral baclofen, or other treatments, do not provide the desired results, ITB Therapy℠ with Lioresal® Intrathecal offers another treatment option.
- Lioresal® Intrathecal offers the unique opportunity to try out intrathecal baclofen to see how it affects severe spasticity in a 1-day screening trial.
- 97% of patients with spasticity of spinal origin1 and 94% of patients with spasticity of cerebral origin have positive responses in the screening trial of Lioresal® Intrathecal.2
- ITB Therapy (Intrathecal Baclofen Therapy) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, ITB Therapy via an implantable infusion system should be reserved for patients unresponsive to oral baclofen or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. This therapy is contraindicated in patients who are hypersensitive to baclofen. Implantation of the infusion system is contraindicated if the patient is of insufficient body size, requires a pump implant deeper than 2.5 cm, or, in the presence of spinal anomalies or active infection.
- Good candidates for a treatment with Lioresal® Intrathecal are those who are clinically stable, understand the risks and benefits associated with ITB Therapy℠ with Lioresal® Intrathecal, are able to return to the clinic for dosage titration and periodic pump refills, have demonstrated a positive response in the screening trial.
- Penn R. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg. 1992;77:236-240.
- Gilmartin R, Bruce D, Storrs B, et al. Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. J Child Neurol. 2000;15(2):71-77.